Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.

Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, Brar R, Baker C, Gluckman TJ, Stucky NL

JAMA internal medicine1 Sept 2024Cited by 251 (Europe PMC)

PMID38976257PMCIDPMC11231910DOI10.1001/jamainternmed.2024.2525PepBankPUB-38976257

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanObservational studyEfficacy outcome
In adults with overweight or obesity, tirzepatide users were more likely than semaglutide users to reach 5% or greater weight loss (hazard ratio 1.76).
In plain wordsIn adults with overweight or obesity, people on tirzepatide were more likely than people on semaglutide to lose at least 5% of their weight.
Peptide
Tirzepatide
Outcome
IncreaseAchieving 5% or greater weight loss
Study
n = 18,386
Comparator
Semaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Hazard ratio
1.76 HR
5% or greater weight loss
Source sentences
Summary
Patients receiving tirzepatide were significantly more likely to achieve weight loss (≥5%; hazard ratio [HR], 1.76, 95% CI, 1.68, 1.84; ≥10%; HR, 2.54; 95% CI, 2.37, 2.73; and ≥15%; HR, 3.24; 95% CI, 2.91, 3.61).
2 context sentences(design, population, supporting numbers)
Summary · context
In this cohort study, adults with overweight or obesity receiving semaglutide or tirzepatide between May 2022 and September 2023 were identified using electronic health record (EHR) data linked to dispensing information from a collective of US health care systems.
Summary · context
Among 41 222 adults meeting the study criteria (semaglutide, 32 029; tirzepatide, 9193), 18 386 remained after propensity score matching.
Report a problemFND-3897625701
02HumanObservational studyEfficacy outcome
In adults with overweight or obesity, tirzepatide users were more likely than semaglutide users to reach 10% or greater weight loss (hazard ratio 2.54).
In plain wordsIn adults with overweight or obesity, people on tirzepatide were more likely than people on semaglutide to lose at least 10% of their weight.
Peptide
Tirzepatide
Outcome
IncreaseAchieving 10% or greater weight loss
Study
n = 18,386
Comparator
Semaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Hazard ratio
2.54 HR
10% or greater weight loss
Source sentences
Summary
Patients receiving tirzepatide were significantly more likely to achieve weight loss (≥5%; hazard ratio [HR], 1.76, 95% CI, 1.68, 1.84; ≥10%; HR, 2.54; 95% CI, 2.37, 2.73; and ≥15%; HR, 3.24; 95% CI, 2.91, 3.61).
2 context sentences(design, population, supporting numbers)
Summary · context
In this cohort study, adults with overweight or obesity receiving semaglutide or tirzepatide between May 2022 and September 2023 were identified using electronic health record (EHR) data linked to dispensing information from a collective of US health care systems.
Summary · context
Among 41 222 adults meeting the study criteria (semaglutide, 32 029; tirzepatide, 9193), 18 386 remained after propensity score matching.
Report a problemFND-3897625702
03HumanObservational studyEfficacy outcome
In adults with overweight or obesity, tirzepatide users were more likely than semaglutide users to reach 15% or greater weight loss (hazard ratio 3.24).
In plain wordsIn adults with overweight or obesity, people on tirzepatide were more likely than people on semaglutide to lose at least 15% of their weight.
Peptide
Tirzepatide
Outcome
IncreaseAchieving 15% or greater weight loss
Study
n = 18,386
Comparator
Semaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Hazard ratio
3.24 HR
15% or greater weight loss
Source sentences
Summary
Patients receiving tirzepatide were significantly more likely to achieve weight loss (≥5%; hazard ratio [HR], 1.76, 95% CI, 1.68, 1.84; ≥10%; HR, 2.54; 95% CI, 2.37, 2.73; and ≥15%; HR, 3.24; 95% CI, 2.91, 3.61).
2 context sentences(design, population, supporting numbers)
Summary · context
In this cohort study, adults with overweight or obesity receiving semaglutide or tirzepatide between May 2022 and September 2023 were identified using electronic health record (EHR) data linked to dispensing information from a collective of US health care systems.
Summary · context
Among 41 222 adults meeting the study criteria (semaglutide, 32 029; tirzepatide, 9193), 18 386 remained after propensity score matching.
Report a problemFND-3897625703
04HumanObservational studyEfficacy outcome
In adults with overweight or obesity, tirzepatide gave a larger on-treatment weight reduction than semaglutide at 3 months (difference -2.4%).
In plain wordsIn adults with overweight or obesity, people on tirzepatide lost more weight than people on semaglutide after 3 months.
Peptide
Tirzepatide
Outcome
DecreasePercentage weight change at 3 months
Study
n = 18,386
Comparator
Semaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3 monthsAs given in this study (human).
Measurements
Weight change difference
−2.4%
3 months
Source sentences
Summary
On-treatment changes in weight were larger for patients receiving tirzepatide at 3 months (difference, -2.4%; 95% CI -2.5% to -2.2%), 6 months (difference, -4.3%; 95% CI, -4.7% to -4.0%), and 12 months (difference, -6.9%; 95% CI, -7.9% to -5.8%).
2 context sentences(design, population, supporting numbers)
Summary · context
In this cohort study, adults with overweight or obesity receiving semaglutide or tirzepatide between May 2022 and September 2023 were identified using electronic health record (EHR) data linked to dispensing information from a collective of US health care systems.
Summary · context
Among 41 222 adults meeting the study criteria (semaglutide, 32 029; tirzepatide, 9193), 18 386 remained after propensity score matching.
Report a problemFND-3897625704
05HumanObservational studyEfficacy outcome
In adults with overweight or obesity, tirzepatide gave a larger on-treatment weight reduction than semaglutide at 6 months (difference -4.3%).
In plain wordsIn adults with overweight or obesity, people on tirzepatide lost more weight than people on semaglutide after 6 months.
Peptide
Tirzepatide
Outcome
DecreasePercentage weight change at 6 months
Study
n = 18,386
Comparator
Semaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Weight change difference
−4.3%
6 months
Source sentences
Summary
On-treatment changes in weight were larger for patients receiving tirzepatide at 3 months (difference, -2.4%; 95% CI -2.5% to -2.2%), 6 months (difference, -4.3%; 95% CI, -4.7% to -4.0%), and 12 months (difference, -6.9%; 95% CI, -7.9% to -5.8%).
2 context sentences(design, population, supporting numbers)
Summary · context
In this cohort study, adults with overweight or obesity receiving semaglutide or tirzepatide between May 2022 and September 2023 were identified using electronic health record (EHR) data linked to dispensing information from a collective of US health care systems.
Summary · context
Among 41 222 adults meeting the study criteria (semaglutide, 32 029; tirzepatide, 9193), 18 386 remained after propensity score matching.
Report a problemFND-3897625705
06HumanObservational studyEfficacy outcome
In adults with overweight or obesity, tirzepatide gave a larger on-treatment weight reduction than semaglutide at 12 months (difference -6.9%).
In plain wordsIn adults with overweight or obesity, people on tirzepatide lost more weight than people on semaglutide after 12 months.
Peptide
Tirzepatide
Outcome
DecreasePercentage weight change at 12 months
Study
n = 18,386
Comparator
Semaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Weight change difference
−6.9%
12 months
Source sentences
Summary
On-treatment changes in weight were larger for patients receiving tirzepatide at 3 months (difference, -2.4%; 95% CI -2.5% to -2.2%), 6 months (difference, -4.3%; 95% CI, -4.7% to -4.0%), and 12 months (difference, -6.9%; 95% CI, -7.9% to -5.8%).
2 context sentences(design, population, supporting numbers)
Summary · context
In this cohort study, adults with overweight or obesity receiving semaglutide or tirzepatide between May 2022 and September 2023 were identified using electronic health record (EHR) data linked to dispensing information from a collective of US health care systems.
Summary · context
Among 41 222 adults meeting the study criteria (semaglutide, 32 029; tirzepatide, 9193), 18 386 remained after propensity score matching.
Report a problemFND-3897625706
07HumanObservational studySafety outcome
In adults with overweight or obesity, rates of gastrointestinal adverse events were similar for tirzepatide and semaglutide.
In plain wordsIn adults with overweight or obesity, stomach and bowel side effects were about as common with tirzepatide as with semaglutide.
Peptide
Tirzepatide
Outcome
No significant changeGastrointestinal adverse events
Study
n = 18,386
Comparator
Semaglutide
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Rates of gastrointestinal AEs were similar between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
In this cohort study, adults with overweight or obesity receiving semaglutide or tirzepatide between May 2022 and September 2023 were identified using electronic health record (EHR) data linked to dispensing information from a collective of US health care systems.
Summary · context
Among 41 222 adults meeting the study criteria (semaglutide, 32 029; tirzepatide, 9193), 18 386 remained after propensity score matching.
Report a problemFND-3897625707
08HumanObservational studySafety outcome
In adults with overweight or obesity, rates of gastrointestinal adverse events were similar for semaglutide and tirzepatide.
In plain wordsIn adults with overweight or obesity, stomach and bowel side effects were about as common with semaglutide as with tirzepatide.
Peptide
Semaglutide
Outcome
No significant changeGastrointestinal adverse events
Study
n = 18,386
Comparator
Tirzepatide
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Rates of gastrointestinal AEs were similar between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
In this cohort study, adults with overweight or obesity receiving semaglutide or tirzepatide between May 2022 and September 2023 were identified using electronic health record (EHR) data linked to dispensing information from a collective of US health care systems.
Summary · context
Among 41 222 adults meeting the study criteria (semaglutide, 32 029; tirzepatide, 9193), 18 386 remained after propensity score matching.
Report a problemFND-3897625708

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 4NCT07513168

Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults

Asian Institute Of Medical Sciencesn = 601 Aug 2025 to est. 1 Dec 2026

Obesity · Weight Reduction · Cardiometabolic Risk Factors

Trial page ClinicalTrials.govUpdated 6 Apr 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 2
9 Oct 2026, 03:07 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.